A novel aminoacid determinant of HIV-1 restriction in the TRIM5α variable 1 region isolated in a random mutagenic screen

Virus Research

Volumn 173, Issue 2, 2013, Pages 306-314

  Pham, Quang Toan ^a   Veillette, Maxime ^a   Brandariz Nuñez, Alberto ^b   Pawlica, Paulina ^a   Thibert Lefebvre, Caroline ^a   Chandonnet, Nadia ^a   Diaz Griffero, Felipe ^b   Berthoux, Lionel ^a  

^a UNIVERSITÉ DU QUÉBEC À TROIS RIVIÈRES   (Canada)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Genetic screen; HIV 1; Random mutagenesis; Restriction; TRIM5

Indexed keywords

AMINO ACID; TRIPARTITE MOTIF PROTEIN 5; VIRUS VECTOR;

ACIDITY; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DNA RESTRICTION; GENE MUTATION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MUTAGENICITY; MUTANT; ORTHOLOGY; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; T LYMPHOCYTE; VIRUS CAPSID; VIRUS ISOLATION;

BINDING SITES; CARRIER PROTEINS; CELL LINE; GENETIC TESTING; HIV-1; HUMANS; MODELS, MOLECULAR; MUTAGENESIS; MUTANT PROTEINS; PROTEIN BINDING; PROTEIN CONFORMATION; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MIRIDAE;

EID: 84876858334     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2013.01.013     Document Type: Article

References (66)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology 1986, 59(2):284-291.
2. Anderson J., Akkina R. TRIM5alpha(rh) expression restricts HIV-1 infection in lentiviral vector-transduced CD34(+)-cell-derived macrophages. Molecular Therapy 2005, 12(4):687-696.
3. Anderson J.L., Campbell E.M., Wu X., Vandegraaff N., Engelman A., Hope T.J. Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. Journal of Virology 2006, 80(19):9754-9760.
4. Battivelli E., Migraine J., Lecossier D., Yeni P., Clavel F., Hance A.J. Gag cytotoxic T lymphocyte escape mutations can increase sensitivity of HIV-1 to human TRIM5alpha, linking intrinsic and acquired immunity. Journal of Virology 2011, 85(22):11846-11854.
5. Berthoux L., Sebastian S., Sayah D.M., Luban J. Disruption of human TRIM5alpha antiviral activity by nonhuman primate orthologs. Journal of Virology 2005, 79(12):7883-7888.
6. Berthoux L., Sebastian S., Sokolskaja E., Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. Journal of Virology 2004, 78(21):11739-11750.
7. Berthoux L., Sebastian S., Sokolskaja E., Luban J. Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(41):14849-14853.
8. Berthoux L., Towers G.J., Gurer C., Salomoni P., Pandolfi P.P., Luban J. As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. Journal of Virology 2003, 77(5):3167-3180.
9. Bérubé J., Bouchard A., Berthoux L. Both TRIM5alpha and TRIMCyp have only weak antiviral activity in canine D17 cells. Retrovirology 2007, 4:68.
10. Biris N., Yang Y., Taylor A.B., Tomashevski A., Guo M., Hart P.J., Diaz-Griffero F., Ivanov D.N. Structure of the rhesus monkey TRIM5alpha PRYSPRY domain, the HIV capsid recognition module. Proceedings of the National Academy of Sciences of the United States of America 2012, 109(33):13278-13283.
11. Black L.R., Aiken C. TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro. Journal of Virology 2010, 84(13):6564-6569.
12. Bounou S., Leclerc J.E., Tremblay M.J. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. Journal of Virology 2002, 76(3):1004-1014.
13. Campbell E.M., Perez O., Anderson J.L., Hope T.J. Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. Journal of Cell Biology 2008, 180(3):549-561.
14. Chakrabarti L.A., Simon V. Immune mechanisms of HIV control. Current Opinion in Immunology 2010, 22(4):488-496.
15. Cowan S., Hatziioannou T., Cunningham T., Muesing M.A., Gottlinger H.G., Bieniasz P.D. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(18):11914-11919.
16. Cullen B.R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. Journal of Virology 2006, 80(3):1067-1076.
17. Diaz-Griffero F., Li X., Javanbakht H., Song B., Welikala S., Stremlau M., Sodroski J. Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5. Virology 2006, 349(2):300-315.
18. Diaz-Griffero F., Perron M., McGee-Estrada K., Hanna R., Maillard P.V., Trono D., Sodroski J. A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus. Virology 2008, 378(2):233-242.
19. Diaz-Griffero F., Qin X.R., Hayashi F., Kigawa T., Finzi A., Sarnak Z., Lienlaf M., Yokoyama S., Sodroski J. A B-box 2 surface patch important for TRIM5alpha self-association, capsid binding avidity, and retrovirus restriction. Journal of Virology 2009, 83(20):10737-10751.
20. Evans D.T., Serra-Moreno R., Singh R.K., Guatelli J.C. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends in Microbiology 2010, 18(9):388-396.
21. Forshey B.M., Shi J., Aiken C. Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. Journal of Virology 2005, 79(2):869-875.
22. Ganser-Pornillos B.K., Chandrasekaran V., Pornillos O., Sodroski J.G., Sundquist W.I., Yeager M. Hexagonal assembly of a restricting TRIM5alpha protein. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(2):534-539.
23. Ganser-Pornillos B.K., von Schwedler U.K., Stray K.M., Aiken C., Sundquist W.I. Assembly properties of the human immunodeficiency virus type 1 CA protein. Journal of Virology 2004, 78(5):2545-2552.
24. Ganser B.K., Li S., Klishko V.Y., Finch J.T., Sundquist W.I. Assembly and analysis of conical models for the HIV-1 core. Science 1999, 283(5398):80-83.
25. Goffinet C., Allespach I., Homann S., Tervo H.M., Habermann A., Rupp D., Oberbremer L., Kern C., Tibroni N., Welsch S., Krijnse-Locker J., Banting G., Krausslich H.G., Fackler O.T., Keppler O.T. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009, 5(3):285-297.
26. Groot F., Welsch S., Sattentau Q.J. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. Blood 2008, 111(9):4660-4663.
27. Haller C., Fackler O.T. HIV-1 at the immunological and T-lymphocytic virological synapse. Biological Chemistry 2008, 389(10):1253-1260.
28. Ikeda Y., Ylinen L.M., Kahar-Bador M., Towers G.J. Influence of gag on human immunodeficiency virus type 1 species-specific tropism. Journal of Virology 2004, 78(21):11816-11822.
29. Kambal A., Mitchell G., Cary W., Gruenloh W., Jung Y., Kalomoiris S., Nacey C., McGee J., Lindsey M., Fury B., Bauer G., Nolta J.A., Anderson J.S. Generation of HIV-1 resistant and functional macrophages from hematopoietic stem cell-derived induced pluripotent stem cells. Molecular Therapy 2011, 19(3):584-593.
30. Kar A.K., Diaz-Griffero F., Li Y., Li X., Sodroski J. Biochemical and biophysical characterization of a chimeric TRIM21-TRIM5alpha protein. Journal of Virology 2008, 82(23):11669-11681.
31. Langelier C.R., Sandrin V., Eckert D.M., Christensen D.E., Chandrasekaran V., Alam S.L., Aiken C., Olsen J.C., Kar A.K., Sodroski J.G., Sundquist W.I. Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. Journal of Virology 2008, 82(23):11682-11694.
32. Li Y., Li X., Stremlau M., Lee M., Sodroski J. Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. Journal of Virology 2006, 80(14):6738-6744.
33. Lienlaf M., Hayashi F., Di Nunzio F., Tochio N., Kigawa T., Yokoyama S., Diaz-Griffero F. Contribution of E3-ubiquitin ligase activity to HIV-1 restriction by TRIM5alpha(rh): structure of the RING domain of TRIM5alpha. Journal of Virology 2011, 85(17):8725-8737.
34. Mangeat B., Gers-Huber G., Lehmann M., Zufferey M., Luban J., Piguet V. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathogens 2009, 5(9):e1000574.
35. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114(1):21-31.
36. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Medicine 2003, 9(11):1398-1403.
37. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. Journal of Biological Chemistry 2004, 279(9):7792-7798.
38. Naviaux R.K., Costanzi E., Haas M., Verma I.M. The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. Journal of Virology 1996, 70(8):5701-5705.
39. Ohkura S., Yap M.W., Sheldon T., Stoye J.P. All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction. Journal of Virology 2006, 80(17):8554-8565.
40. Owens C.M., Yang P.C., Gottlinger H., Sodroski J. Human and simian immunodeficiency virus capsid proteins are major viral determinants of early, postentry replication blocks in simian cells. Journal of Virology 2003, 77(1):726-731.
41. Perez-Caballero D., Hatziioannou T., Yang A., Cowan S., Bieniasz P.D. Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity. Journal of Virology 2005, 79(14):8969-8978.
42. Perez-Caballero D., Hatziioannou T., Zhang F., Cowan S., Bieniasz P.D. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. Journal of Virology 2005, 79(24):15567-15572.
43. Perron M.J., Stremlau M., Lee M., Javanbakht H., Song B., Sodroski J. The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. Journal of Virology 2007, 81(5):2138-2148.
44. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera-a visualization system for exploratory research and analysis. Journal of Computational Chemistry 2004, 25(13):1605-1612.
45. Pham Q.T., Bouchard A., Grutter M.G., Berthoux L. Generation of human TRIM5alpha mutants with high HIV-1 restriction activity. Gene Therapy 2010, 17(7):859-871.
46. Richardson M.W., Carroll R.G., Stremlau M., Korokhov N., Humeau L.M., Silvestri G., Sodroski J., Riley J.L. Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. Journal of Virology 2008, 82(22):11117-11128.
47. Rold C.J., Aiken C. Proteasomal degradation of TRIM5alpha during retrovirus restriction. PLoS Pathogens 2008, 4(5):e1000074.
48. Rossi J.J., June C.H., Kohn D.B. Genetic therapies against HIV. Nature Biotechnology 2007, 25(12):1444-1454.
49. Roy A., Kucukural A., Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature Protocols 2010, 5(4):725-738.
50. Rudnicka D., Feldmann J., Porrot F., Wietgrefe S., Guadagnini S., Prevost M.C., Estaquier J., Haase A.T., Sol-Foulon N., Schwartz O. Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets through polysynapses. Journal of Virology 2009, 83(12):6234-6246.
51. Sakuma R., Noser J.A., Ohmine S., Ikeda Y. Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nature Medicine 2007, 13(5):631-635.
52. Sawyer S.L., Wu L.I., Emerman M., Malik H.S. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(8):2832-2837.
53. Sebastian S., Luban J. TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retrovirology 2005, 2:40.
54. Sebastian S., Sokolskaja E., Luban J. Arsenic counteracts human immunodeficiency virus type 1 restriction by various TRIM5 orthologs in a cell type-dependent manner. Journal of Virology 2006, 80(4):2051-2054.
55. Shi J., Aiken C. Saturation of TRIM5 alpha-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology 2006, 350(2):493-500.
56. Song B., Gold B., O'Huigin C., Javanbakht H., Li X., Stremlau M., Winkler C., Dean M., Sodroski J. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates. Journal of Virology 2005, 79(10):6111-6121.
57. Stremlau M., Owens C.M., Perron M.J., Kiessling M., Autissier P., Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004, 427(6977):848-853.
58. Stremlau M., Perron M., Lee M., Li Y., Song B., Javanbakht H., Diaz-Griffero F., Anderson D.J., Sundquist W.I., Sodroski J. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(14):5514-5519.
59. Stremlau M., Perron M., Welikala S., Sodroski J. Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. Journal of Virology 2005, 79(5):3139-3145.
60. Uchil P.D., Quinlan B.D., Chan W.T., Luna J.M., Mothes W. TRIM E3 ligases interfere with early and late stages of the retroviral life cycle. PLoS Pathogens 2008, 4(2):e16.
61. Wu X., Anderson J.L., Campbell E.M., Joseph A.M., Hope T.J. Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(19):7465-7470.
62. Yap M.W., Nisole S., Stoye J.P. A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Current Biology 2005, 15(1):73-78.
63. Zhang F., Perez-Caballero D., Hatziioannou T., Bieniasz P.D. No effect of endogenous TRIM5alpha on HIV-1 production. Nature Medicine 2008, 14(3):235-236. (author reply 236-8).
64. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008, 9:40.
65. Zhao G., Ke D., Vu T., Ahn J., Shah V.B., Yang R., Aiken C., Charlton L.M., Gronenborn A.M., Zhang P. Rhesus TRIM5alpha disrupts the HIV-1 capsid at the inter-hexamer interfaces. PLoS Pathogens 2011, 7(3):e1002009.
66. Zufferey R., Nagy D., Mandel R.J., Naldini L., Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnology 1997, 15(9):871-875.